Is intermittent fasting good for weight loss? Experts weigh in
is the superstar amongst those who aim to lose weight. From 6/8, 5:2, alternate-day fasting, and 24-hour fasts, there are different kinds of fasts, depending on their potential
effects. But whether this
really helps with weight loss is still the calorie-burning question! A new study has looked into the potential benefits of intermittent fasting and suggests that it could offer even more.
Tired of too many ads? go ad free now
A study by the researchers from the University of Mississippi suggests that intermittent fasting paired with exercise increases
over the activity alone. The study published in the
found that when healthy adults pair an eight-hour eating window with regular exercise, they lose more fat, without sacrificing lean muscle, compared to exercise alone.
'We saw that this did lead to more fat loss and reduced body fat percentage over time when healthy adults were following both exercise with time-restricting eating, compared to those who were only exercising for at least 4 weeks. It is important to note
,' Nadeeja Wijayatunga, assistant professor of nutrition and hospitality management, said in a statement.
Wijayatunga and co-author Michael Hays, a tactical dietitian and recent graduate of the university, conducted a systematic review and meta-analysis of 15 previous studies on the subject, spanning the past decade. Time-restricted eating is one of many diets included in the umbrella term intermittent fasting.
'People like time-restricted eating because they feel it's easier to adhere to because they don't have to think too much.
It's all about time, not calorie-counting or watching out for certain foods,' she said.
The popularity of
has quickly risen, especially in the United States, with 12% of Americans having tried it, according to the 2023 International Food and Health Survey.
However, the science surrounding time-restricted eating is still developing, Hays said.
How to prevent muscle loss?
'For some people, this may be a good technique to help with body composition goals.
Tired of too many ads? go ad free now
It's just another tool, but more studies need to come out to really understand how this works in humans,' Hays added.
Hays also noted that there was a slight difference between people who exercised while following a time-restricted diet and those who used exercise alone, but the two groups were already very healthy individuals.
'In most cases, these were healthy adults. They were already physically fit and already had exercise routines.
When you already have athletic, lean people and you decrease their body fat percentage, that's significant,' Hays said.
Though time-restricted diet is hailed for its weight loss effects, it has been criticized for possibly leading to a loss of lean mass, including all the muscles, organs, and other tissues that make up the human body.
'We need healthy muscles. Muscles are really important for the body and for your metabolism.
If we lose muscle, it may impact our metabolic systems, and it just decreases mobility overall,' Wijayatunga said.
This study found that when time-restricted eating is paired with exercise, it does not lead to a reduction in lean mass, even for those who lost body fat.
'That's why you want to couple diet with exercise. When you're losing weight, you never want to lose lean tissue. You want to lose fat,' Hays said.
'What I'd recommend is implementing healthy habits in a way that you, as an individual, can maintain, with guidance from a health care professional,' she added.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
9 hours ago
- Mint
Trump wants cheaper drugs like Europe has. How it works.
President Donald Trump doesn't just want to bring down prescription drug prices for Americans. He wants European countries to raise them to make up the revenue that drugmakers would lose from his policy. Trump is proposing a so-called most-favored-nation pricing model, which would set U.S. drug prices at the lowest level in other wealthy countries. But the pharmaceutical industry isn't buying into tying drug prices in the U.S. to prices in Europe—at least not knowing the details of the president's proposal. More details about the government's pricing model could come this week. On May 12, Trump directed government health officials to benchmark drug prices to international standards within 30 days. The lobbying group PhRMA, with members including U.S. pharma giants Eli Lilly, Pfizer, Johnson & Johnson, and AbbVie, has argued there are two reasons why U.S. drug prices are high: foreign countries not paying 'their fair share" for medicines, and middlemen such as pharmacy-benefit managers. Today, U.S. drug pricing is largely market driven. It involves negotiations between drug manufacturers, pharmacy-benefit managers, healthcare insurers and providers. European countries do it much differently. Each has its own way of determining drug prices, but most follow one of two broad approaches. The first approach, which Germany and France use, considers the overall clinical effectiveness of a new medicine. How does the new treatment compare to existing ones? Does it have added therapeutic benefits? If the new drug is substantially better, its price would reflect that. A second approach, used by the U.K., the Netherlands, and Sweden, analyzes cost effectiveness. This model not only compares the new drug to existing ones but also assesses the incremental value that the medicine brings to the health system. After the assessments, negotiations between drugmakers and the countries begin. Because many European countries have national health systems, they are in a strong negotiation position. If government negotiators think a medicine is too expensive for its effectiveness, they won't recommend its use. How Trump's MFN policy would work in practice isn't clear. Drug prices would probably be based on list prices in Europe since the prices paid by national health systems, or net prices, are confidential. The president's open-ended directive, laid out in an executive order, has many wondering how the U.S. could raise prices in Europe. Trump has made clear he wants to close the gap between U.S. and international prices, and has suggested he would use tariffs and export controls to achieve his goal. In theory, drugmakers could set list prices higher in Europe as long as it doesn't affect net prices, health policy expert Dr. Huseyin Naci told Barron's. In the U.K., for example, a higher list price could still lower the prices in other European countries. 'So that would still not be an acceptable approach to many other European countries," said Naci, who is associate professor of health policy at the London School of Economics. Overhauling Europe's decades-old pricing approaches would require fundamental changes to their pricing regulations—and there will be 'little appetite or ability" to alter them, Naci added. Cost is another complicating factor. 'Pharmaceutical spending is already one of the top categories of spending in many countries in terms of healthcare expenditure, so there's little room to accommodate higher prices and spending for pharmaceuticals in Europe," according to Naci. How Trump is planning to make Europeans pay more for drugs is the big question. He could use tariffs and trade negotiations as leverage. In early April, the president said a 'major" tax on pharmaceutical imports is coming 'very shortly," however nothing has been announced yet. In a trade agreement with the U.K. a month later, there is a provision on pharmaceuticals that states the U.K. will 'endeavor to improve the overall environment for pharmaceutical companies." What that means in practice still isn't clear. Write to Elsa Ohlen at
Mint
15 hours ago
- Mint
These diabetes drugs are finding new life as an antiaging hack
Some health-obsessed Americans believe the next antiaging therapeutic already exists—in the medicine cabinets of millions of diabetes patients. The widely used class of drugs, called SGLT2 inhibitors and sold under brand names such as Jardiance and Farxiga, have been on the market for over a decade as Type 2 diabetes medications. They have also gained regulatory approval to treat conditions like heart failure and kidney disease. Recently, though, the drugs have emerged as a hot topic on popular health podcasts and Reddit forums for longevity enthusiasts, many of whom don't suffer from any of those conditions. Instead, they are adding SGLT2 inhibitors to a roster of hacks they hope will help them live healthier for longer—or in other words, increase their healthspan. The drugs work by helping the kidneys release extra glucose from the body through urine, improving blood-sugar levels. While there are no studies of whether they can extend the lives of healthy humans, a growing body of evidence shows they help protect against multiple age-related diseases and reduce mortality rates for patients with certain chronic conditions. Some researchers believe they may also affect the fundamental biology of aging. 'This is probably the drug class of our era," says Dr. Timothy Gong, section physician leader for heart failure and transplant cardiology at Baylor University Medical Center, who has researched SGLT2 inhibitors. 'You see cardiologists, nephrologists, endocrinologists, even general internists as well, just getting so excited." Gong says he wouldn't be surprised to take an SGLT2 inhibitor one day, once they are studied more, though he's free from heart issues and diabetes. Yet it's too early to prescribe it for longevity benefits in otherwise healthy patients. 'I don't think that the evidence is strong enough yet for us to be able to say that," he says. Right now, use of SGLT2 inhibitors for potential antiaging benefits is limited mostly to a growing community of so-called biohackers, who seek to optimize their health through experimentation with gadgets, behaviors and various medicines and supplements. Because most take it off-label—meaning, for a nonapproved use—the drugs typically aren't covered by insurance and can cost hundreds of dollars a month out of pocket. Dave Aiello, a Boston chiropractor who doesn't have diabetes, began experimenting with the drugs after learning about a promising study in mice. The 38-year-old wanted to get ahead of health problems but was disenchanted by what he saw as a reactive approach to disease in conventional medicine. 'I'm trying to see if I can just stay as healthy as possible for as long as possible," says Aiello, who has been taking an SGLT2 inhibitor called empagliflozin since 2022. He also takes the kidney-transplant drug rapamycin off-label and has previously taken the diabetes pill metformin—both of which have gained traction as potential longevity boosters, too. He was particularly impressed by research showing SGLT2 inhibitors can help the body manage blood sugar more efficiently, which in turn supports cardiometabolic health. He says he's encouraged by the results so far: Between 2022 and 2024, Aiello's hemoglobin A1C, a measure of average blood sugar, fell to 4.6% from 5.1%, his laboratory test results show. The drugs aren't free of potential side effects, including increased risk of urinary-tract infections, dehydration, and in rare cases, severe genital infections and a life-threatening condition called diabetic ketoacidosis. When Aiello first started taking empagliflozin, he felt dehydrated and experienced fatigue and brain fog. Those side effects have subsided since he decreased his dose and has made sure to take in more electrolytes. 'I'm a little more willing to take some risks that could potentially affect me in the short term if I do think that there might be a benefit," Aiello says. It isn't clear precisely how SGLT2 inhibitors might protect against the ravages of aging, but the research in mice offers clues. In 2020, a National Institute on Aging-funded study found that one SGLT2 inhibitor called canagliflozin extended the lives of male—but not female—mice by 14%. One theory is that the drugs help slow the aging process partly by blunting blood-sugar spikes. Scientists say that by driving insulin levels down, these drugs promote fat burning and create an anti-inflammatory effect that mimics calorie restriction, which studies suggest can slow the pace of aging. Still, many drugs that work in mice don't work in humans, says Richard A. Miller, who led the study and is director of the Glenn Center for Biology of Aging Research at the University of Michigan. His lab is now studying how the small molecules inside slow-aging mice change over time. If a drug in humans produces these same metabolomic shifts seen in slow-aging mice, he says, it would provide more confidence that it could slow aging in people. 'We still have a lot of work to do to prove that the drugs do the same thing in people," says Miller. 'The hint here is that it's actually slowing the aging rate." Alan Vuong, who works in sales in Austin, Texas, started taking the SGLT2 inhibitor dapagliflozin this year after hearing a podcast interview with Miller. The 34-year-old has a family history of Type 2 diabetes and wanted to lower his fasting insulin level, a measure of metabolic health, from normal to optimal. He spends about $150 a month on his longevity protocol, which includes a dozen drugs and supplements, and has seen his insulin levels drop since starting the medication. Other than having to use the bathroom in the middle of the night more often, a known side effect of the drugs, Vuong hasn't noticed other physical side effects. 'My end goal is to extend lifespan, but more importantly, healthspan," he says. 'I'm willing to take that gamble."
Time of India
18 hours ago
- Time of India
NASA Layoffs: Is Trump's budget cut approved by Congress? NASA asks employees to opt for early retirement, deferred resignation, or voluntary separation. Here's last date and terms of departure
NASA has introduced a range of new programs aimed at reducing its workforce. These changes follow proposed budget cuts by the Trump administration for the 2026 fiscal year. The programs are voluntary and give employees multiple options for leaving the agency. New Programs for Staff Exit NASA sent memos to employees on June 9, announcing early retirement, deferred resignation, and voluntary separation incentive options. These programs are part of a larger workforce reduction effort. The goal is to reduce the number of NASA employees significantly by 2026. Also Read: 1923 Season 1 Netflix: Why will Netflix air only Season 1? Here's how and when to stream internationally by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like If You Eat Ginger Everyday for 1 Month This is What Happens Tips and Tricks Undo Reasons Behind Staff Reductions The Trump administration has proposed a 24% cut to NASA's overall budget for 2026. This proposal aims to lower the employee count from 17,391 to 11,853, a 32% drop. The proposed budget is still under review by Congress and not yet finalized. Deadline for Employee Decisions NASA has asked employees to decide by July 25 if they want to participate in the new staff reduction options. Those who opt into the Deferred Resignation Program will likely stop working soon afterward but will continue to receive pay until January 9, 2026. Live Events Also Read: This is why nearly 700,000 Americans lost Medicaid coverage in one month Terms of Departure According to the agency, employees who sign the separation agreement will start administrative leave within one to two weeks. Most participants are expected to complete their employment by January 9, 2026. Some critical staff may receive approval to delay their departure until April 1 or as late as September 30, 2026. Similar Changes Across Other Agencies NASA's new programs follow similar moves at other government agencies. Around 75,000 federal workers have already taken deferred resignation offers. Changes have also occurred at NASA's Jet Propulsion Laboratory (JPL), which recently ended remote work. Most of the 5,500 staff at JPL are now required to return to the office or resign. FAQs Why is NASA reducing its workforce now? NASA is responding to proposed budget cuts for 2026. These cuts aim to reduce spending and the number of employees across the agency. When will most participating employees leave NASA? Most employees who accept the offer will stop working by January 9, 2026. Some may stay until April or September 2026, based on need.
